Literature DB >> 25028695

An engagement factor for caregiver radiation dose assessment with radioiodine treatment.

Hyun Kuk Lee1, Seong Jong Hong2, Kyu Hwan Jeong3, Jae Won Jung4, Seong Min Kim5, Yun-Hee Kang6, Man Seok Han7.   

Abstract

This study aims to suggest ways to better manage thyroid cancer patients treated with high- and low-activity radioiodine ((131)I) by assessing external radiation doses to family members and caregivers and the level of radiation in the surrounding environment. The radiation doses to caregivers of 33 inpatients (who were quarantined in the hospital for 2-3 d after treatment) and 31 outpatients who received radioiodine treatment after thyroidectomy were measured using passive thermoluminescence dosemeters. In this study, 33 inpatients were administered high-activity (100-200 mCi) (131)I, and 31 outpatients were administered low-activity (30 mCi) (131)I. The average doses to caregivers were measured at 0.61 mSv for outpatients and 0.16 mSv for inpatients. The total integrated dose of the recovery (recuperation) rooms where the patients stayed after release from hospital was measured to be 0.83 mSv for outpatients and 0.23 mSv for inpatients. To reflect the degree of engagement between the caregiver and the patient, considering the duration and distance between two during exposure, the authors used the engagement factor introduced by Jeong et al. (Estimation of external radiation dose to caregivers of patients treated with radioiodine after thyroidectomy. Health Phys 2014; 106: :466-474.). This study presents a new engagement factor (K-value) of 0.82 obtained from the radiation doses to caregivers of both in- and out-patients treated with high- and low-activity radioiodine, and based on this new value, this study presented a new predicted dose for caregivers. A patient treated with high-activity radioiodine can be released after 24 h of isolation, whereas outpatients treated with low-activity radioiodine should be isolated for at least 12 h.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25028695     DOI: 10.1093/rpd/ncu231

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  1 in total

1.  Do Current Radiation Safety Guidelines allow the Safe Release of a Thyroid Cancer Patient after High-dose Radioiodine Therapy? An Indian Perspective.

Authors:  Subhash Chand Kheruka; Nilesh Shankar; Manish Ora; Sanjay Gambhir
Journal:  Indian J Nucl Med       Date:  2021-06-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.